Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Fineline Cube Jan 16, 2026
Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Fineline Cube Jan 16, 2026
Company Deals

J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions

Fineline Cube Jan 16, 2026
Company Deals

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent

Fineline Cube Jan 16, 2026
Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Fineline Cube Jan 15, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Gan & Lee’s Insulin Glargine Wins Ethiopia Approval, Challenging Sanofi’s Dominance

Fineline Cube Jan 16, 2026
Company Drug

Zelgen’s ZGGS18 & ZG005 Cleared by NMPA for Advanced Solid Tumor Studies

Fineline Cube Jan 16, 2026
Company Drug

Simcere Receives NMPA Clearance for SIM0348 Clinical Study

Fineline Cube Dec 30, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products...

Company Deals

Skynor Medical Raises RMB 100 Million in Financing Round for Market Expansion

Fineline Cube Dec 30, 2022

Skynor Medical, a Shanghai-based manufacturer of nerve and peripheral blood vessel implantation and interventional devices,...

Company Deals

Sichuan Kelun Completes RMB 1.5 Billion Financing Round for Kelun-Biotech

Fineline Cube Dec 30, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced the completion of a financing...

Company Drug

Everest Medicines’ Nefecon Receives Priority Review Recommendation from CDE

Fineline Cube Dec 30, 2022

China-based Everest Medicines (HKG: 1952) has announced that the Center for Drug Evaluation (CDE) of...

Company Drug

BrightGene Receives NMPA Approval for BGM0504 Clinical Trial

Fineline Cube Dec 30, 2022

China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has announced that it has received clinical...

Drug

Anhui Anke Biotechnology Receives NMPA Approval for AK2017 Clinical Study

Fineline Cube Dec 30, 2022

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced receiving approval from the...

Company Drug

AstraZeneca’s Nexium Approved by NMPA for Adolescent GERD Treatment

Fineline Cube Dec 30, 2022

UK-based pharmaceutical major AstraZeneca (NASDAQ: AZN) has announced receiving market approval from the National Medical...

Company Deals

Sino Biopharmaceutical Secures Rights to Shionogi’s COVID-19 Therapy Ensitrelvir

Fineline Cube Dec 30, 2022

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia Tai Tianqing...

Company Deals

Shenzhen Core Medical Raises ‘Hundreds of Millions’ in Series C Financing

Fineline Cube Dec 30, 2022

Shenzhen-based heart failure mechanical circulatory support solutions provider, Shenzhen Core Medical Technology Co., Ltd, has...

Company

Sinovac Reports H1 2022 Financials Amid COVID-19 Vaccine Demand Decline

Fineline Cube Dec 30, 2022

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has released its financial report for the first half...

Company Drug

Junshi Biosciences’ JT001 (VV116) Shows Non-Inferiority to Paxlovid in COVID-19 Trial

Fineline Cube Dec 29, 2022

The results of a Phase III clinical study for China-based Junshi Biosciences’ (HKG: 1877, SHA:...

Company Drug Legal / IP

Hainan Shuangcheng Files Paragraph IV Patent Declaration for Paclitaxel, Albumin-Bound

Fineline Cube Dec 29, 2022

China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has announced a Paragraph IV patent declaration...

Company Drug

Grand Pharma’s COVID-19 Therapy GS221 Shows Promising Safety Profile

Fineline Cube Dec 29, 2022

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its clinical study for the...

Company Drug

Fosun Pharma Launches Online Registration for BioNTech COVID-19 Vaccine in Hong Kong

Fineline Cube Dec 29, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced a new initiative...

Company Drug

Immunotech Biopharm’s CAR-T-19-D2 IND Filing Accepted by NMPA

Fineline Cube Dec 29, 2022

China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that...

Company Medical Device

Acotec Scientific Holdings Receives NMPA Approvals for YAN and P-Conic Balloon

Fineline Cube Dec 29, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving market approvals from the National...

Company Drug

CanSino Biologics Updates Data from COVID-19 Vaccine Clinical Studies

Fineline Cube Dec 29, 2022

China-based CanSino Biologics (HKG: 6185) has provided data updates from three clinical studies for its...

Company Deals

Fortune Care Raises Over RMB 100 Million in Series C+ Financing Round

Fineline Cube Dec 29, 2022

China-based household healthcare and nursing brand Fortune Care reportedly raised over RMB 100 million (USD...

Company Deals

Guangzhou Mygene Raises ‘Hundreds of Millions’ in Series C Financing Led by Efund Capital

Fineline Cube Dec 29, 2022

China-based molecular diagnostic product developer Guangzhou Mygene Medical Technology Co., Ltd reportedly raised “hundreds of...

Company

WuXi Biologics Receives First GMP Certificate from Ireland HPRA

Fineline Cube Dec 28, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced receiving...

Posts pagination

1 … 525 526 527 … 610

Recent updates

  • InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline
  • Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership
  • Gan & Lee’s Insulin Glargine Wins Ethiopia Approval, Challenging Sanofi’s Dominance
  • Zelgen’s ZGGS18 & ZG005 Cleared by NMPA for Advanced Solid Tumor Studies
  • J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Company Drug

Gan & Lee’s Insulin Glargine Wins Ethiopia Approval, Challenging Sanofi’s Dominance

Company Drug

Zelgen’s ZGGS18 & ZG005 Cleared by NMPA for Advanced Solid Tumor Studies

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.